Oncolytics Biotech Inc ONCY

Candel Therapeutics not addressing metastatic PDAC

[Noteable]

April 04, 2024 - Candel Therapeutics oncolytic virus (herpes virus) addresses borderline resectable pancreatic ductal adenocarcinoma (PDAC) and not metastatic PDAC, in which ONCY's pelareorep + immune checkpoint inhibitors has demonstrated related postive results.

https://www.onclive.com/view/can-2409-plus-valacyclovir-generates-positive-phase-2-survival-results-in-pdac

A borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC) is a tumor with limited vascular involvement that is technically resectable but with a high risk of positive margins (R1 resection).

https://www.dovepress.com/borderline-resectable-pancreatic-cancer-challenges-for-clinical-manage-peer-reviewed-fulltext-article-CMAR

[Noteable]

After a protocol amendment in 2022, Candel Therapeutics discontinued the enrollment of patients with locally advanced PDAC to focus exclusively on those with the lesser challenging borderline resectable disease. Locally advanced PDAC is non-metastatic however LA-PDAC involves the local invasion of adjacent structures. Patients with locally advanced pancreatic cancer may undergo surgery to

[Noteable]

Candel Therapeutics Phase 2 orderline resectable PDAC data was on 13 patients. Prolonged and sustained survival was observed after experimental treatment with CAN-2409 in patients with borderline resectable PDAC (n=13)

[Noteable]

Should read: ...  borderline resectable PDAC data was on 13 patients

[Noteable]

" .... notable clusters of CD8-positive granzyme B-positive cytotoxic tumor infiltrating lymphocytes, dendritic cells, and B cells were detected within the tumor microenvironment, which is not seen with the SOC alone " ... and which is has been demonstrated in multiple ONCY clinical trials, most notably in ONCY's AWARE-1 Phase 2 study.

[Noteable]

On Candel Therapeutics' oncolytic virus borderline resectable PDAC data, Candel closed up +281% today.

[Noteable]

Unlike ONCY's pelareorep, Candel Therapeutics herpes virus OV does NOT have Rare/Orphan designation by the FDA, and therefore would not be eligible for Accelerated Approval, as would ONCY .. which places ONCY years ahead of Candel Therapeutics in terms of gaining marketing approval.

[Noteable]

Should read: " Unlike ONCY's pelareorep, Candel Therapeutics herpes virus OV does NOT have Rare/Orphan designation by the FDA, for the treatment of pancreatic cancer ...." Candel Therapeutics does have Orphan designation for the treatment of gliomas. 

[ENEMENEMYNEMO]

Yes the difference being though is that Candels product works!!! 

[Noteable]

So if Candel Therapeutics OV works ... then it goes that so does ONCY's pelareorep in combinaton with an immune checkpoint inhibitor - thus making ONCY an even greater  acquisition candidate for Big Pharma - particularly since pelareorep can be granted an Accelerated Approval  and on the market in short order. Let me remind you that ONCY's Phase 2 Goblet study showed that

[Noteable]

Just so the dumbstruck understand - Candel Therapeutics' herpes virus is being trialed in combination with generic agents that don't have any signficant value to any Big Pharma with an I/O agent that is facing patent expiration, such as immune checkpoint inhibitors, bispecfic ADCs, CAR-T therapies, and small molecules such as CDK4/6 and PARP inhibitors, for example. Big Pharma, with

[ENEMENEMYNEMO]

So please then explain to us members whom you feel are of lesser intelligence than yourself why their stock skyrocketed 300% and ours languishes where it is.  Oh is that your mommy calling from upstairs , go eat first , I can wait for your predictable response...

[Noteable]

Well "Mo"'s last post shows that with he and his inept partners, Larry and Curly Joe, the Three Stooges are alive and well.

[Azzak34]

You used whom wrong there. You've not learned the lessons of the other dopes on here. Don't try to sound smart and mess it up, it reveals your stupidity. 

[ENEMENEMYNEMO]

Nice deflection! Sorry second language failures

[Azzak34]

Haha look who's deflecting! Your English is fine, your intellect is the problem. 

[ENEMENEMYNEMO]

Dang it ! You got me again ! ...but still...why is this not delivering after 25 years???

[Azzak34]

OVs have been the ugly girl at the discotheque, the kind of ones you get. But they're perty-ing up fast and we're well placed when they do. 

[ENEMENEMYNEMO]

At least I'm always going home with something....unlike this stock

[Azzak34]

Spoken like a true loser. Why did you buy back in by the way? 

[Lesalpes29]

Stupid fight! Have a good day.

[ENEMENEMYNEMO]

To annoy you (and apparently LesAlpes.... 'whom' also appears to lack a sense of wit...however I think the previous mention of Larry,Curly and Mo got him excited)

[Azzak34]

You invested money in to a company you don't believe in to annoy me? Seems like a lie.  Yeah he pops up bow and again with incoherent nonsense. You should be on his team. 

[Hydroqc]

That is meant to be clear. You are here to annoy others. Pretty dumb statement..You are the Dumber of the Dumb team.

[Noteable]

Candel Therapeutics up another 47% this morning @ US$9.40 

[Peladawn]

Thanks for that, Note.....sure makes ya wonder what percentage Oncy share price will rise the day they announce results from Goblet with patients still alive and still going strong.....And then the commencement of enrollment in one or maybe even both of the Phase 3 trials.

[Noteable]

Yes Peladawn -- that was the point I was making ... and that ONCY's detractors weren't interested in admitting.

[Noteable]

 Candel Therapeutics up + 300% today.